Compare DOMH & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOMH | PLRX |
|---|---|---|
| Founded | 1967 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.3M | 71.5M |
| IPO Year | 2010 | 2020 |
| Metric | DOMH | PLRX |
|---|---|---|
| Price | $2.57 | $1.13 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 186.9K | ★ 370.1K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 23.45% | N/A |
| EPS Growth | ★ 34.03 | 29.97 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $123,104,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 578.41 | N/A |
| 52 Week Low | $2.19 | $1.02 |
| 52 Week High | $8.40 | $1.95 |
| Indicator | DOMH | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.12 | 55.16 |
| Support Level | $2.29 | $1.12 |
| Resistance Level | $3.42 | $1.37 |
| Average True Range (ATR) | 0.21 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 22.11 | 52.38 |
Dominari Holdings Inc is a holding company that, through its various subsidiaries, is engaged in wealth management, investment banking, sales and trading, asset management, and insurance. In addition to capital investment, Dominari provides management support to the executive teams of its subsidiaries, helping them to operate efficiently and reduce costs under a streamlined infrastructure. The Company operates in two reportable business segments: Dominari Financial and Legacy AIkido, with the majority of revenue from Dominari Financial.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.